Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Int. J. Mol. Sci. 2011, 12(1), 24-38; doi:10.3390/ijms12010024
Review

Biomarkers in Rare Disorders: The Experience with Spinal Muscular Atrophy

* ,
 and
Received: 10 November 2010; in revised form: 6 December 2010 / Accepted: 16 December 2010 / Published: 23 December 2010
(This article belongs to the Special Issue Biomarkers)
View Full-Text   |   Download PDF [187 KB, uploaded 19 June 2014]   |   Browse Figure
Abstract: Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by homozygous mutations of the SMN1 gene. Based on clinical severity, three forms of SMA are recognized (type I–III). All patients have at least one (usually 2–4) copies of a highly homologous gene (SMN2) which produces insufficient levels of functional SMN protein, due to alternative splicing of exon7. Recently, evidence has been provided that SMN2 expression can be enhanced by different strategies. The availability of potential candidates to treat SMA has raised a number of issues, including the availability of data on the natural history of the disease, the reliability and sensitivity of outcome measures, the duration of the studies, and the number and clinical homogeneity of participating patients. Equally critical is the availability of reliable biomarkers. So far, different tools have been proposed as biomarkers in SMA, classifiable into two groups: instrumental (the Compound Motor Action Potential, the Motor Unit Number Estimation, and the Dual-energy X-ray absorptiometry) and molecular (SMN gene products dosage, either transcripts or protein). However, none of the biomarkers available so far can be considered the gold standard. Preclinical studies on SMA animal models and double-blind, placebo-controlled studies are crucial to evaluate the appropriateness of biomarkers, on the basis of correlations with clinical outcome.
Keywords: spinal muscular atrophy; SMA; SMN; biomarker spinal muscular atrophy; SMA; SMN; biomarker
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Tiziano, F.D.; Neri, G.; Brahe, C. Biomarkers in Rare Disorders: The Experience with Spinal Muscular Atrophy. Int. J. Mol. Sci. 2011, 12, 24-38.

AMA Style

Tiziano FD, Neri G, Brahe C. Biomarkers in Rare Disorders: The Experience with Spinal Muscular Atrophy. International Journal of Molecular Sciences. 2011; 12(1):24-38.

Chicago/Turabian Style

Tiziano, Francesco D.; Neri, Giovanni; Brahe, Christina. 2011. "Biomarkers in Rare Disorders: The Experience with Spinal Muscular Atrophy." Int. J. Mol. Sci. 12, no. 1: 24-38.



Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert